Meeting Banner
Abstract #0697

Precision medicine advanced by full body imaging biomarkers, whole genomic sequencing and blood-based measures

Natalie M Schenker-Ahmed1, Y C Hou1, Christine Leon Swisher1, Hung-Chun Yu1, Robyn Heister1, Lori Napier1, Saints M Dominguez1, Nathaniel Hernandez1, Michael Doney1, and David S Karow1

1Human Longevity, Inc., San Diego, CA, United States

We present the findings from 1190 presumed healthy patients evaluated at a precision medicine clinic. We performed deep quantitative multimodal phenotyping and genotyping comprising quantitative whole-body imaging, whole genome sequencing, and advanced blood-based biomarkers. Within this cohort, medically significant findings included aneurysms, newly identified tumors, coronary artery disease, metabolic disease, cardiac arrhythmia, myocardial disease, and neurodegenerative risk. Forty percent of “healthy” patients had a new clinically significant finding that was not previously known. For this 40%, we are able to provide quantitative continuous metrics that enable individuals to make informed decisions to mitigate their health risks.

This abstract and the presentation materials are available to members only; a login is required.

Join Here